{"product_id":"teriperatide","title":"Teriperatide","description":"\u003cp\u003eTERIPARATIDE (PTH 1-34)\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eBone Formation | Osteoblast Activity | Skeletal Health\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eTeriparatide is a synthetic form of the biologically active 1-34 amino-acid fragment of human parathyroid hormone (PTH). Unlike many osteoporosis therapies that primarily slow bone breakdown, teriparatide has an anabolic effect on bone, stimulating new bone formation when administered intermittently.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eTeriparatide activates the PTH1 receptor, influencing calcium and phosphate metabolism while preferentially stimulating osteoblast activity over osteoclast activity with once-daily exposure.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eAreas of Clinical Use \u0026amp; Research\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e• New bone formation\u003c\/p\u003e\n\u003cp\u003e• Increased bone mineral density\u003c\/p\u003e\n\u003cp\u003e• Osteoblast activity\u003c\/p\u003e\n\u003cp\u003e• Osteoporosis and fracture-risk reduction\u003c\/p\u003e\n\u003cp\u003e• Glucocorticoid-associated osteoporosis\u003c\/p\u003e\n\u003cp\u003e• Skeletal remodeling and repair\u003c\/p\u003e\n\u003cp\u003e• PTH1-receptor signaling\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eEstablished Clinical Dosage\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eThe FDA-approved dosage of teriparatide is:\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e20 mcg subcutaneously once daily\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eAdministration is into the thigh or abdominal region.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eTreatment beyond two years during a patient's lifetime is generally considered only when the patient remains, or again becomes, at high risk for fracture.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eWhy Teriparatide Is Interesting\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eThe timing of PTH exposure matters. Continuous PTH exposure can favor bone resorption, whereas brief intermittent exposure to teriparatide preferentially stimulates osteoblastic activity and new bone formation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eClinical studies have demonstrated increases in bone mineral density, and teriparatide is approved for certain patients at high risk for osteoporotic fracture.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eStorage\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eCommercial teriparatide pens are stored refrigerated at 2–8°C (36–46°F) and should not be frozen. Storage requirements for compounded, lyophilized, or other formulations may differ and should follow the specifications of the individual product.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003ePrescription medication. Dosage and treatment duration should be determined by an appropriately licensed healthcare professional.\u003c\/p\u003e","brand":"Research Peptide Market","offers":[{"title":"750mcg","offer_id":44366177337422,"sku":null,"price":0.0,"currency_code":"USD","in_stock":false}],"url":"https:\/\/researchpeptidemarket.com\/products\/teriperatide","provider":"Research Peptide Market","version":"1.0","type":"link"}